In-Silico Drug Discovery Market - GLOBAL:2022

Market Report Coverage :
Start Year : 2021 - Forecast Year : 2031 - Start Value : $2,395.3 Million in 2021 - Forecast Value : $6,515.3 Million by 2031 - CAGR % : 0.11%
Description :
Market Report Coverage - In-Silico Drug DiscoveryMarket Segmentation• Workflow - Discovery, Pre-Clinical Tests, and Clinical Trials• Products - Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service• Technology - Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies• Software - Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software• End User - Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End UsersRegional Segmentation• North America: U.S., Canada• Europe: Germany, France, Italy, U.K., Spain, Russia, and Rest-of- Europe• Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific• Latin America: Brazil, Mexico, Rest-of-Latin America• Rest-of-the-WorldMarket Growth Drivers• Rising Emphasis on Reduction in Medical Errors• Technological Advancements in the Field of Computational Biology• Integration of Blockchain Technology in Interoperability• Rising Adoption of Cloud-Based Application for Drug DiscoveryMarket Challenges• Lack of High Complexity Testing Centers• Expensive In-Silico Drug Discovery Procedures and Decline in the Number of Approved Drugs• High Capital Requirement Hampering the Expansion of Global ReachMarket Opportunities• Massive Scope for Adoption of In-Silico Drug Discovery in Developing Nations• Adoption of Artificial Intelligence in In-Silico Drug DiscoveryKey Companies ProfiledAragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC., Collaborative Drug Discovery Inc., Dassault Systemes, e-therapeutics plc., Evotec, Insilico Medicine, Ligand Pharmaceuticals Incorporated, Numerate, Inc., PerkinElmer Inc., Schrödinger, Inc., Selvita, Simulations Plus, Tracxn Technologies, WuXi AppTecKey Questions Answered in this Report:• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments: o Workflow (Discovery, Pre-Clinical Tests, and Clinical Trials) o Products (Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service) o Technology (Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies) o Software (Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software) o End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the major market drivers, restraints, and opportunities in the global in-silico drug discovery market?• What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?• How is each segment of the global in-silico drug discovery market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?• What are the key developmental strategies implemented by the major players to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions for in-silico drug discovery?• Who are the leading players with significant offerings to the global in-silico drug discovery market? What is the current market dominance for each of these leading players?• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which in-silico drug discovery workflow type has the most promising growth? • What are the major technologies that are employed in the global in-silico drug discovery market? Which is the dominating technology?• Who are the primary end users of the global in-silico drug discovery market? Which is the fastest-growing end-user segment in the global in-silico drug discovery market?• Who are the key manufacturers in the global in-silico drug discovery market, and what are their contributions? Also, what is the growth potential of each major in-silico drug discovery manufacturer?• What is the scope of the global in-silico drug discovery market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which in-silico drug discovery technology and end user dominate these regions?• What are the emerging trends in the global in-silico drug discovery market? How are these trends revolutionizing the diagnostic procedure? • Which technologies are anticipated to break through the in-silico drug discovery regime?• Which companies are anticipated to be highly disruptive in the future and why?• Which regulatory procedures are required to unify the approval process for the emerging in-silico drug discovery market? How will these enhance the reimbursement scenario?• What are the gaps in regularizing in-silico drug discovery adoption in regular healthcare routines? How are these gaps being tackled?Market OverviewIn-silico drug discovery methods can help in identifying drug targets via bioinformatics tools. In addition, the methods can also be used to analyze the target structures for possible binding active sites. The use of computational methods and computers permeates all aspects of drug discovery and drug design. The methods are facilitating the access of massive amounts of data generated and transforming the extensive complex biological data into useful knowledge for the drug discovery process. These computational tools offer the advantage of delivering new drug candidates more quickly and at a lower cost.BIS Research's healthcare experts have found the in-silico drug discovery market to be one of the stable markets, and the global market is predicted to grow from $2,129.8 million in 2020 to $6,515.3 million in 2031 and is expected to grow with a CAGR of 10.52% during the forecast period 2021-2031.Factors fueling the growth of the market include the rising emphasis on reduction in medical errors, technological advancements in the field of computational biology, and the rising adoption of cloud-based applications in drug discovery procedures. New drug compounds have been developed using computational methods successfully. The developments in computational biology have eased the data analytics and analysis phases of sequencing and have resulted in fewer turnaround times and greater accuracy.Within the research report, the market has been segmented based on workflow, product, technology, software type, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the prevalence of infectious diseases and various types of cancer globally has created a buzz among companies to invest in advanced technologies such as artificial intelligence.Based on region, North America holds the largest share, owing to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France U.K. Spain Russia Rest-of-EuropeAsia-Pacific China India Japan Australia South Korea Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin America (RoLA)Rest-of-the-World
Keywords :
In-Silico Drug Discovery Market, In-Silico Drug Discovery Industry, In-Silico Drug Discovery Report, In-Silico Drug Discovery Market Forecasts, In-Silico Drug Discovery Market Trends, In-Silico Drug Discovery Market Companies, In-Silico Drug Discovery Market Analysis, In-Silico Drug Discovery Industry Analysis, What is In-Silico Drug Discovery, In-Silico Drug Discovery Definition, In-Silico Drug Discovery Market Competitive Landscape, In-Silico Drug Discovery Market Drivers, In-Silico Drug Discovery Market Segments, In-Silico Drug Discovery Market Outlook, In-Silico Drug Discovery Market Opportunity, In-Silico Drug Discovery Market Growth, In-Silico Drug Discovery Market Share, In-Silico Drug Discovery Market Size, In-Silico Drug Discovery Market by Products, In-Silico Drug Discovery Market by Workflow, In-Silico Drug Discovery Market by Software Type, In-Silico Drug Discovery Market by Technology, In-Silico Drug Discovery Market by End User, In-Silico Drug Discovery Market by Region, Software In-Silico Drug Discovery Market, Software-as-a-Service In-Silico Drug Discovery Market, Consultancy-as-a-Service In-Silico Drug Discovery Market, Target Identification In-Silico Drug Discovery Market, Bioinformatics In-Silico Drug Discovery Market, Reverse Docking In-Silico Drug Discovery Market, Protein Structure Prediction In-Silico Drug Discovery Market, Target Validation In-Silico Drug Discovery Market, Lead Discovery In-Silico Drug Discovery Market, Pharmacophore In-Silico Drug Discovery Market, Library Design In-Silico Drug Discovery Market, Molecular Modeling and De Novo Drug Design Software In-Silico Drug Discovery Market, Pharmacophore Modeling Software In-Silico Drug Discovery Market, Artificial Intelligence In-Silico Drug Discovery Market, Graphics Processing Unit In-Silico Drug Discovery Market, In-Silico Fishing In-Silico Drug Discovery Market, RNN for Drug Design In-Silico Drug Discovery Market, Contract Research Organizations In-Silico Drug Discovery Market, Pharmaceutical and Biopharmaceutical Companies In-Silico Drug Discovery Market, Academic and Research Institutes In-Silico Drug Discovery Market, North America In-Silico Drug Discovery Market, Europe In-Silico Drug Discovery Market, Asia-Pacific In-Silico Drug Discovery Market, Latin America In-Silico Drug Discovery Market
Press Release :
The premium market intelligence report published by BIS Research on the title Global In-Silico Drug Discovery Market highlights that the market is projected to reach $6,515.3 million by 2031. The study also highlights that the market is set to witness a CAGR of 10.52% during the forecast period 2021-2031.In-silico drug discovery approach is based on computational methods. The methods include management and the design of initial hit identification through virtual screening of small molecule libraries, optimization of the affinity as well as selectivity of hits, and improving the properties of the lead compounds. Computational drug designing approaches are used for the whole drug discovery process and virtual chemical library design.Who should buy this report?• In-silico drug discovery manufacturers who are planning to invest in one of the large established markets• Companies involved in technology development of in-silico drug discovery• Companies in the drug discovery market• Companies involved in developing bioinformatics tools data analysis, visualization, sharing, and storageTo gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include workflow, products, software type, technology, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.The premium market intelligence by BIS Research also highlights the opportunities existing in the market, including the high scope for adoption of in-silico drug discovery approach in emerging nations, increased use of bioinformatics tools, and providing a solution for the treatment of chronic diseases. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.To emphasize the dominance of the North America segment in the regional segmentation of the global in-silico drug discovery market in 2020 and 2031, Nitish Kumar Singh, Principal Analyst - BIS Research, states, "North America is the leading contributor to the global in-silico drug discovery market. It contributed approximately 41.62% to the global market value in 2020. This region is anticipated to grow at a CAGR of 10.43% during the forecast period 2021-2031 and will continue dominating the global market in 2031. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 10.86% during the forecast period 2021- 2031.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 17 leading companies, market participants, and vendors. The key players profiled in the report include Aragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC., Collaborative Drug Discovery Inc., Dassault Systemes, e-therapeutics plc., Evotec, Insilico Medicine, Ligand Pharmaceuticals Incorporated, Numerate, Inc., PerkinElmer Inc., Schrödinger, Inc., Selvita, Simulations Plus, Tracxn Technologies, and WuXi AppTec.The study also offers strategic recommendations that can help organizations track various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Insightful Questions Covered to Enable Companies to take Strategic Decisions• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments: o Workflow (Discovery, Pre-Clinical Tests, and Clinical Trials) o Products (Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service) o Technology (Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies) o Software (Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software) o End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the major market drivers, restraints, and opportunities in the global in-silico drug discovery market?• What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?• How is each segment of the global in-silico drug discovery market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?• What are the key developmental strategies implemented by the major players to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions for in-silico drug discovery?• Who are the leading players with significant offerings to the global in-silico drug discovery market? What is the current market dominance for each of these leading players?• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which in-silico drug discovery workflow type has the most promising growth? • What are the major technologies that are employed in the global in-silico drug discovery market? Which is the dominating technology?• Who are the primary end users of the global in-silico drug discovery market? Which is the fastest-growing end-user segment in the global in-silico drug discovery market?• Who are the key manufacturers in the global in-silico drug discovery market, and what are their contributions? Also, what is the growth potential of each major in-silico drug discovery manufacturer?• What is the scope of the global in-silico drug discovery market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which in-silico drug discovery technology and end user dominate these regions?• What are the emerging trends in the global in-silico drug discovery market? How are these trends revolutionizing the diagnostic procedure? • Which technologies are anticipated to break through the in-silico drug discovery regime?• Which companies are anticipated to be highly disruptive in the future and why?• Which regulatory procedures are required to unify the approval process for the emerging in-silico drug discovery market? How will these enhance the reimbursement scenario?• What are the gaps in regularizing in-silico drug discovery adoption in regular healthcare routines? How are these gaps being tackled?
Companies Mentioned :
Aragen Life Sciences Pvt. Ltd.Curia Global, Inc.Certara, USA.Charles RiverChemical Computing Group ULC.Collaborative Drug Discovery Inc.Dassault Systemese-therapeutics plc.EvotecInsilico MedicineLigand Pharmaceuticals IncorporatedNumerate, Inc.PerkinElmer Inc.Schrödinger, Inc.SelvitaSimulations PlusTracxn TechnologiesWuXi AppTec
Press Release :
The premium market intelligence report published by BIS Research on the title Global In-Silico Drug Discovery Market highlights that the market is projected to reach $6,515.3 million by 2031. The study also highlights that the market is set to witness a CAGR of 10.52% during the forecast period 2021-2031.In-silico drug discovery approach is based on computational methods. The methods include management and the design of initial hit identification through virtual screening of small molecule libraries, optimization of the affinity as well as selectivity of hits, and improving the properties of the lead compounds. Computational drug designing approaches are used for the whole drug discovery process and virtual chemical library design.Who should buy this report?• In-silico drug discovery manufacturers who are planning to invest in one of the large established markets• Companies involved in technology development of in-silico drug discovery• Companies in the drug discovery market• Companies involved in developing bioinformatics tools data analysis, visualization, sharing, and storageTo gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include workflow, products, software type, technology, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.The premium market intelligence by BIS Research also highlights the opportunities existing in the market, including the high scope for adoption of in-silico drug discovery approach in emerging nations, increased use of bioinformatics tools, and providing a solution for the treatment of chronic diseases. The study is majorly centered on the sub-segments and micro-segments of the different commercialized products in the market.To emphasize the dominance of the North America segment in the regional segmentation of the global in-silico drug discovery market in 2020 and 2031, Nitish Kumar Singh, Principal Analyst - BIS Research, states, "North America is the leading contributor to the global in-silico drug discovery market. It contributed approximately 41.62% to the global market value in 2020. This region is anticipated to grow at a CAGR of 10.43% during the forecast period 2021-2031 and will continue dominating the global market in 2031. However, the Asia-Pacific region is expected to grow at an impressive CAGR of 10.86% during the forecast period 2021- 2031.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 17 leading companies, market participants, and vendors. The key players profiled in the report include Aragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC., Collaborative Drug Discovery Inc., Dassault Systemes, e-therapeutics plc., Evotec, Insilico Medicine, Ligand Pharmaceuticals Incorporated, Numerate, Inc., PerkinElmer Inc., Schrödinger, Inc., Selvita, Simulations Plus, Tracxn Technologies, and WuXi AppTec.The study also offers strategic recommendations that can help organizations track various products, trends, and applications that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Insightful Questions Covered to Enable Companies to take Strategic Decisions• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Following are the segments: o Workflow (Discovery, Pre-Clinical Tests, and Clinical Trials) o Products (Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service) o Technology (Artificial Intelligence, Graphics Processing Unit (GPU), and Other Technologies) o Software (Molecular Modeling and De Novo Drug Design Software, Pharmacophore Modeling Software) o End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, Academic and Research Institutes, and Other End Users) o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)• What are the major market drivers, restraints, and opportunities in the global in-silico drug discovery market?• What are the underlying structures resulting in the emerging trends within the global in-silico drug discovery market?• How is each segment of the global in-silico drug discovery market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?• What are the key developmental strategies implemented by the major players to sustain in the competitive market?• What are the key regulatory implications in developed and developing regions for in-silico drug discovery?• Who are the leading players with significant offerings to the global in-silico drug discovery market? What is the current market dominance for each of these leading players?• What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which in-silico drug discovery workflow type has the most promising growth? • What are the major technologies that are employed in the global in-silico drug discovery market? Which is the dominating technology?• Who are the primary end users of the global in-silico drug discovery market? Which is the fastest-growing end-user segment in the global in-silico drug discovery market?• Who are the key manufacturers in the global in-silico drug discovery market, and what are their contributions? Also, what is the growth potential of each major in-silico drug discovery manufacturer?• What is the scope of the global in-silico drug discovery market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which in-silico drug discovery technology and end user dominate these regions?• What are the emerging trends in the global in-silico drug discovery market? How are these trends revolutionizing the diagnostic procedure? • Which technologies are anticipated to break through the in-silico drug discovery regime?• Which companies are anticipated to be highly disruptive in the future and why?• Which regulatory procedures are required to unify the approval process for the emerging in-silico drug discovery market? How will these enhance the reimbursement scenario?• What are the gaps in regularizing in-silico drug discovery adoption in regular healthcare routines? How are these gaps being tackled?
Headline :
Global In-Silico Drug Discovery Market to Reach $6,515.3 Million by 2031
Table of Contents :
1 Markets1.1 Product Definition1.1.1 Inclusion and Exclusion1.2 Global In-Silico Drug Discovery Market Size and Forecast1.3 Global In-Silico Drug Discovery Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario1.3.1 Realistic Growth Scenario1.3.2 Conservative Growth Scenario1.3.3 Optimistic Growth Scenario1.4 Current Global In-Silico Drug Discovery Market Landscape1.4.1 Market Availability for In-Silico Drug Discovery1.4.2 In-Silico Drug Discovery Market Technology Trends1.5 Market Dynamics1.5.1 Overview1.5.2 Impact Analysis1.5.3 Market Drivers1.5.3.1 Rising Emphasis on Reduction in Medical Errors1.5.3.2 Technological Advancements in the Field of Computational Biology1.5.3.3 Integration of Blockchain Technology in Interoperability1.5.3.4 Rising Adoption of Cloud-Based Application for Drug Discovery1.5.4 Market Restraints1.5.4.1 Lack of High Complexity Testing Centers1.5.4.2 Expensive In-Silico Drug Discovery Procedures and Decline in the Number of Approved Drugs1.5.4.3 High Capital Requirement Hampering the Expansion of Global Reach1.5.5 Market Opportunities1.5.5.1 Massive Scope for Adoption of In-Silico Drug Discovery in Developing Nations1.5.5.2 Adoption of Artificial Intelligence in In-Silico Drug Discovery1.6 COVID-19 Impact on Global In-Silico Drug Discovery Market1.6.1 Overview1.6.2 Impact on the Market Growth1.6.3 Impact on Clinical Trial1.6.4 Impact on R&D1.7 Competitive Landscape1.7.1 Acquisitions1.7.2 Synergistic Activities1.7.3 Product Launches and Upgradations1.7.4 Business Expansion1.7.5 Patent Approval, Fundings, Investments, and Marketing Strategy1.7.6 Market Share Analysis1.7.7 Growth Share Analysis1.8 Industry Insights1.8.1 Regulatory Framework in North America1.8.2 Regulatory Framework in Europe1.8.3 Regulatory Framework in Asia-Pacific1.9 Patent Analysis1.9.1 Patent Filing Trend2 Products2.1 Overview2.1.1 Software2.1.2 Software-as-a-Service (Cloud)2.1.3 Consultancy-as-a-Service3 Workflow3.1 Overview3.2 Discovery3.2.1 Target Identification3.2.1.1 Bioinformatics3.2.1.2 Reverse Docking3.2.1.3 Protein Structure Prediction3.2.2 Target Validation3.2.3 Lead Discovery3.2.3.1 Library Design3.2.3.2 Pharmacophore3.3 Pre-Clinical Tests3.4 Clinical Trials4 Software Type4.1 Overview4.1.1 Molecular Modeling and De Novo Drug Design Software4.1.2 Pharmacophore Modeling Software5 Technology5.1 Overview5.1.1 Artificial Intelligence5.1.1.1 Computational Methods Used by Advanced AI Companies5.1.1.2 Use of Artificial Intelligence to Combat COVID-19 Pandemic5.1.2 Graphics Processing Unit5.1.3 Other Technologies5.1.3.1 In-Silico Fishing5.1.3.2 RNN for Drug Design6 End-User6.1 Overview6.1.1 Contract Research Organizations6.1.2 Pharmaceutical and Biopharmaceutical Companies6.1.3 Academic and Research Institutes6.1.4 Other End Users (Hospitals and Other Care Facilities)7 Region7.1 Overview7.2 North America7.2.1 North America In-Silico Drug Discovery Market (by Technology)7.2.2 U.S.7.2.3 Canada7.3 Europe7.3.1 Europe In-Silico Drug Discovery Market (by Technology)7.3.2 Germany7.3.3 U.K.7.3.4 France7.3.5 Italy7.3.6 Russia7.3.7 Spain7.3.8 Rest-of-Europe7.4 Asia-Pacific (APAC)7.4.1 Asia-Pacific In-Silico Drug Discovery Market (by Technology)7.4.2 China7.4.3 India7.4.4 Japan7.4.5 Australia7.4.6 South Korea7.4.7 Rest-of-Asia-Pacific7.5 Latin America (LATAM)7.5.1 Latin America In-Silico Drug Discovery Market (by Technology)7.5.2 Brazil7.5.3 Mexico7.5.4 Rest-of-Latin America7.6 Rest-of-the-World (RoW)7.6.1 Rest-of-the-World In-Silico Drug Discovery Market (by Technology)8 Markets - Competitive Benchmarking & Company Profiles8.1 Competitive Benchmarking8.2 Aragen Life Sciences Pvt. Ltd. (GVK Biosciences Pvt. Ltd.)8.2.1 Company Overview8.2.2 Role of Aragen Life Sciences Pvt. Ltd. in the Global In-Silico Drug Discovery Market8.2.3 SWOT Analysis8.3 Curia Global, Inc. (Albany Molecular Research Inc.)8.3.1 Company Overview8.3.2 Role of Curia Global, Inc. in the Global In-Silico Drug Discovery Market8.3.3 SWOT Analysis8.4 Certara, USA.8.4.1 Company Overview8.4.2 Role of Certara, USA. in the Global In-Silico Drug Discovery Market8.4.3 SWOT Analysis8.5 Charles River8.5.1 Company Overview8.5.2 Role of Charles River in the Global In-Silico Drug Discovery Market8.5.3 Financials8.5.4 SWOT Analysis8.6 Chemical Computing Group ULC. (CCG)8.6.1 Company Overview8.6.2 Role of Chemical Computing Group ULC. in the Global In-Silico Drug Discovery Market8.6.3 SWOT Analysis8.7 Collaborative Drug Discovery Inc. (CDD)8.7.1 Company Overview8.7.2 Role of Collaborative Drug Discovery Inc., in the Global In-Silico Drug Discovery Market8.7.3 SWOT Analysis8.8 Dassault Systemes8.8.1 Company Overview8.8.2 Role of Dassault Systemes in the Global In-Silico Drug Discovery Market8.8.3 Financials8.8.4 Key Insights About Financial Health of the Company8.8.5 SWOT Analysis8.9 e-therapeutics plc.8.9.1 Company Overview8.9.2 Role of e-therapeutics plc. in the Global In-Silico Drug Discovery Market8.9.3 Financials8.9.4 Key Insights About Financial Health of the Company8.9.5 SWOT Analysis8.1 Evotec (Cyprotex)8.10.1 Company Overview8.10.2 Role of Evotec in the Global In-Silico Drug Discovery Market8.10.3 Financials8.10.4 Key Insights About Financial Health of the Company8.10.5 SWOT Analysis8.11 Insilico Medicine8.11.1 Company Overview8.11.2 Role of Insilico Medicine in the Global In-Silico Drug Discovery Market8.11.3 SWOT Analysis8.12 Ligand Pharmaceuticals Incorporated (Icagen, Inc.)8.12.1 Company Overview8.12.2 Role of Ligand Pharmaceuticals Incorporated in the Global In-Silico Drug Discovery Market8.12.3 Financials8.12.4 Key Insights About Financial Health of the Company8.12.5 SWOT Analysis8.13 Numerate, Inc.8.13.1 Company Overview8.13.2 Role of Numerate Inc. in the Global In-Silico Drug Discovery Market8.13.3 SWOT Analysis8.14 PerkinElmer Inc.8.14.1 Company Overview8.14.2 Role of PerkinElmer Inc., in the Global In-Silico Drug Discovery Market8.14.3 Financials8.14.4 Key Insights About Financial Health of the Company8.14.5 SWOT Analysis8.15 Schrödinger, Inc.8.15.1 Company Overview8.15.2 Role of Schrödinger, Inc. in the Global In-Silico Drug Discovery Market8.15.3 Financials8.15.4 Key Insights About Financial Health of the Company8.15.5 SWOT Analysis8.16 Selvita8.16.1 Company Overview8.16.2 Role of Selvita in the Global In-Silico Drug Discovery Market8.16.3 SWOT Analysis8.17 Simulations Plus8.17.1 Company Overview8.17.2 Role of Simulations Plus in the Global In-Silico Drug Discovery Market8.17.3 Financials8.17.4 Key Insights About Financial Health of the Company8.17.5 SWOT Analysis8.18 Tracxn Technologies (Novo Informatics Pvt. Ltd.)8.18.1 Company Overview8.18.2 Role of Tracxn Technologies in the Global In-Silico Drug Discovery Market8.18.3 SWOT Analysis8.19 WuXi AppTec8.19.1 Company Overview8.19.2 Role of WuXi AppTec in the Global In-Silico Drug Discovery Market8.19.3 Financials8.19.4 Key Insights About Financial Health of the Company8.19.5 SWOT AnalysisList of Figures Figure 1: Cost-Benefit Analysis between Conventional and In-Silico MethodFigure 2: Global In-Silico Drug Discovery Market (Realistic and Optimistic Scenario), $Million, 2020-2031Figure 3: Impact Analysis of Market Drivers and Market Challenges on the Global In-Silico Drug Discovery MarketFigure 4: Share of Key Market Strategies and Developments, January 2018–January 2022Figure 5: Global In-Silico Drug Discovery Market Snapshot, $Million, 2020-2031Figure 6: Global In-Silico Drug Discovery Market (by Workflow), $Million, 2020 Vs. 2031Figure 7: Global In-Silico Drug Discovery Market (by Product), $Million, 2020 Vs. 2031Figure 8: Global In-Silico Drug Discovery Market (by Software), $Million, 2020 Vs. 2031Figure 9: Global In-Silico Drug Discovery Market SnapshotFigure 10: Global In-Silico Drug Discovery Market Research MethodologyFigure 11: Global In-Silico Drug Discovery Market: SegmentationFigure 12: Global In-Silico Drug Discovery Market Incremental Opportunity, $Million, 2020-2031Figure 13: Global In-Silico Drug Discovery Market Size and Growth Potential (Realistic Scenario), $Million, 2020-2031Figure 14: Global In-Silico Drug Discovery Market Size and Growth Potential (Conservative Scenario), $Million, 2020-2031Figure 15: Global In-Silico Drug Discovery Market Size and Growth Potential (Optimistic Scenario), $Million, 2020-2031Figure 16: Various Steps of In-Silico Drug Discovery ProcessFigure 17: Impact AnalysisFigure 18: Summary of Drug Discovery Process Overlayed with Computational Approach and Methods Used for In-Silico Drug DesignFigure 19: Number of Approved Drugs from 2015-2019Figure 20: Impact of COVID-19 on In-Silico Drug Discovery MarketFigure 21: Share of Key Developments and Strategies, January 2018-January 2022Figure 22: Share of Acquisitions (by Company), January 2018-January 2021Figure 23: Synergistic Activities Share (by Company), January 2018-January 2022Figure 24: Product Launches and Upgradations (by Company), January 2018–December 2021Figure 25: Share of Business Expansion Activities (by Company), January 2018-December 2021Figure 26: Market Share Analysis for Global In-Silico Drug Discovery Market, $Million, 2019 and 2020Figure 27: Growth Share Analysis of Global In-Silico Drug Discovery Market (by Technology), 2020-2031Figure 28: Year-Wise Analysis of Patents Related to In-Silico Drug DiscoveryFigure 29: Share of Global In-Silico Drug Discovery Market (by Product), $Million, 2020 and 2031Figure 30: Global In-Silico Drug Market (Software), $Million, 2020-2031Figure 31: Global In-Silico Drug Market (Software-as-a-Service), $Million, 2020-2031Figure 32: Global In-Silico Drug Discovery Market (Consultancy-as-a-Service), $Million, 2020-2031Figure 33: Global In-Silico Drug Discovery Market (by Workflow)Figure 34: Global In-Silico Drug Discovery Market (by Workflow), $Million, 2020-2031Figure 35: Global In-Silico Drug Discovery Market (Target Identification), $Million, 2020-2031Figure 36: Global In-Silico Drug Discovery Market (Bioinformatics), $Million, 2020-2031Figure 37: Global In-Silico Drug Discovery Market (Reverse Docking), $Million, 2020-2031Figure 38: Global In-Silico Drug Discovery Market (Protein Structure Prediction), 2020-2031Figure 39: Global In-Silico Drug Discovery Market (Target Validation), $Million, 2020-2031Figure 40: Global In-Silico Drug Discovery Market (Lead Discovery), $Million, 2020-2031Figure 41: Global In-Silico Drug Discovery Market (Library Design), $Million, 2020-2031Figure 42: Global In-Silico Drug Discovery Market (Pharmacophore), $Million, 2020-2031Figure 43: Global In-Silico Drug Discovery Market (Pre-Clinical Tests), $Million, 2020-2031Figure 44: Global In-Silico Drug Discovery Market (Clinical Trials), $Million, 2020-2031Figure 45: Global In-Silico Drug Discovery Market (by Software Type), $Million, 2020 and 2031Figure 46: Global In-Silico Drug Discovery Market (Molecular Modeling and De Novo Drug Design Software), 2020-2031Figure 47: Global In-Silico Drug Market (Pharmacophore Modeling Software), $Million, 2020-2031Figure 48: Share of Global In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031Figure 49: Global In-Silico Drug Discovery Market (Artificial Intelligence), $Million, 2020-2031Figure 50: Global In-Silico Drug Discovery Market (Graphics Processing Unit), $Million, 2020-2031Figure 51: Global In-Silico Drug Discovery Market (Other Technologies), $Million, 2020-2031Figure 52: Evolutionary De Novo Drug Design Using RNNFigure 53: Global In-Silico Drug Discovery Market (by End User), $Million, 2020 and 2031Figure 54: Global In-Silico Drug Discovery Market (Contract Research Organizations), $Million, 2020-2031Figure 55: Global In-Silico Drug Discovery Market (Pharmaceutical and Biopharmaceutical Companies), $Million, 2020-2031Figure 56: Global In-Silico Drug Discovery Market (Academic and Research Institutes), $Million, 2020-2031Figure 57: Global In-Silico Drug Discovery Market (Oher End Users), $Million, 2020-2031Figure 58: Global In-Silico Drug Discovery Market (by Region), $Million, 2020-2031Figure 59: Share of North America In-Silico Drug Discovery Market Revenue (by Country), $Million, 2020 and 2031Figure 60: North America: Market DynamicsFigure 61: North America In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031Figure 62: U.S. In-Silico Drug Discovery Market, $Million, 2020-2031Figure 63: Canada In-Silico Drug Discovery Market, $Million, 2020-2031Figure 64: Europe In-Silico Drug Discovery Market (by Country), $Million, 2020 and 2031Figure 65: Europe: Market DynamicsFigure 66: Europe In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031Figure 67: Germany In-Silico Drug Discovery Market, $Million, 2020-2031Figure 68: U.K. In-Silico Drug Discovery Market, $Million, 2020-2031Figure 69: France In-Silico Drug Discovery Market, $Million, 2020-2031Figure 70: Italy In-Silico Drug Discovery Market, $Million, 2020-2031Figure 71: Russia In-Silico Drug Discovery Market, $Million, 2020-2031Figure 72: Spain In-Silico Drug Discovery Market, $Million, 2020-2031Figure 73: Rest-of-Europe In-Silico Drug Discovery Market, $Million, 2020-2031Figure 74: APAC: Market DynamicsFigure 75: Asia-Pacific In-Silico Drug Discovery Market (by Country), $Million, 2020 and 2031Figure 76: Asia-Pacific In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031Figure 77: China In-Silico Drug Discovery Market, $Million, 2020-2031Figure 78: India In-Silico Drug Discovery Market, $Million, 2020-2031Figure 79: Japan In-Silico Drug Discovery Market, $Million, 2020-2031Figure 80: Australia In-Silico Drug Discovery Market, $Million, 2020-2031Figure 81: South Korea In-Silico Drug Discovery Market, $Million, 2020-2031Figure 82: Rest-of-Asia-Pacific In-Silico Drug Discovery Market, $Million, 2020-2031Figure 83: LATAM: Market DynamicsFigure 84: Latin America In-Silico Drug Discovery Market (by Country), $Million 2020 and 2031Figure 85: Latin America In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031Figure 86: Brazil In-Silico Drug Discovery Market, $Million, 2020-2031Figure 87: Mexico In-Silico Drug Discovery Market, $Million, 2020-2031Figure 88: Rest-of-Latin America In-Silico Drug Discovery Market, $Million, 2020-2031Figure 89: Rest-of-the-World In-Silico Drug Discovery Market, $Million, 2020-2031Figure 90: Rest-of-the-World In-Silico Drug Discovery Market (by Technology), $Million, 2020 and 2031Figure 91: Share of Key Company ProfilesFigure 92: Product Portfolio: Aragen Life Sciences Pvt. Ltd.Figure 93: Aragen Life Sciences Pvt. Ltd.: SWOT AnalysisFigure 94: Curia Global, Inc.: Product PortfolioFigure 95: Curia Global, Inc.: SWOT AnalysisFigure 96: Certara, USA.: Product PortfolioFigure 97: Certara, USA.: SWOT AnalysisFigure 98: Charles River.: Product PortfolioFigure 99: Charles River: Overall Financials, $Million, 2018-2020Figure 100: Charles River: Revenue (by Segment), $Million, 2018-2020Figure 101: Charles River: SWOT AnalysisFigure 102: Chemical Computing Group ULC.: Product PortfolioFigure 103: Chemical Computing Group ULC.: SWOT AnalysisFigure 104: Collaborative Drug Discovery Inc. (CDD): Overall Product PortfolioFigure 105: Collaborative Drug Discovery Inc. (CDD): SWOT AnalysisFigure 106: Dassault Systemes: Product OfferingsFigure 107: Dassault Systemes: Overall Financials, $Million, 2018-2020Figure 108: Dassault Systemes.: R&D Expenditure, $Million, 2018-2020Figure 109: Dassault Systemes: SWOT AnalysisFigure 110: e-therapeutics plc.: Product PortfolioFigure 111: e-therapeutics plc.: Overall Financials, $Million, 2019-2021Figure 112: e-therapeutics plc.: R&D Expenditure, $Million, 2019-2021Figure 113: e-therapeutics plc.: SWOT AnalysisFigure 114: Evotec: Product OfferingsFigure 115: Evotec: Overall Financials, $Million, 2018-2020Figure 116: Evotec: R&D Expenditure, $Million, 2018-2020Figure 117: Evotec: SWOT AnalysisFigure 118: Insilico Medicine: Product PortfolioFigure 119: Insilico Medicine: SWOT AnalysisFigure 120: Ligand Pharmaceuticals Incorporated: Overall Product PortfolioFigure 121: Ligand Pharmaceuticals Incorporated: Overall Financials, $Million, 2018-2020Figure 122: Ligand Pharmaceuticals Incorporated: R&D Expenditure, $Million, 2018-2020Figure 123: Ligand Pharmaceuticals, Inc: SWOT AnalysisFigure 124: Numerate Inc.: Overall Product PortfolioFigure 125: Numerate Inc.: SWOT AnalysisFigure 126: PerkinElmer Inc.: Product Portfolio for Global In-Silico Drug Discovery MarketFigure 127: PerkinElmer Inc.: Overall Financials, $Million, 2018-2020Figure 128: PerkinElmer Inc.: Revenue (by Segment), $Million, 2018-2020Figure 129: PerkinElmer Inc.: R&D Expenditure, $Million, 2018-2020Figure 130: PerkinElmer Inc.: SWOT AnalysisFigure 131: Schrödinger, Inc.: Product Portfolio for Global In-Silico Drug Discovery MarketFigure 132: Schrödinger, Inc.: Overall Financials, $Million, 2018-2020Figure 133: Schrödinger, Inc.: R&D Expenditure, $Million, 2018-2020Figure 134: Schrödinger, Inc.: SWOT AnalysisFigure 135: Selvita: Product PortfolioFigure 136: Selvita: SWOT AnalysisFigure 137: Simulations Plus: Product PortfolioFigure 138: Simulations Plus.: Overall Financials, $Million, 2019-2021Figure 139: Simulations Plus: R&D Expenditure, $Million, 2019-2021Figure 140: Simulations Plus: SWOT AnalysisFigure 141: Tracxn Technologies: Product PortfolioFigure 142: Tracxn Technologies Company: SWOT AnalysisFigure 143: WuXi AppTec: Product PortfolioFigure 144: WuXi AppTec.: Overall Financials, $Million, 2018-2020Figure 145: WuXi AppTec: R&D Expenditure, 2018-2020Figure 146: WuXi AppTec: SWOT AnalysisList of Tables Table 1: List of Few Cloud-Based Solutions Used for VS and Target FishingTable 2: COVID-19 Impact on Global In-Silico Drug Discovery MarketTable 3: Approved Products Launch by Various Manufacturers During COVID-19Table 4: List of Companies using AI for COVID-19 TreatmentTable 5: Impact of COVID-19 on Drug TrialTable 6: Regulatory Framework for In-Silico Drug Discovery Market in North AmericaTable 7: Regulatory Framework for In-Silico Drug Discovery Market in EuropeTable 8: Regulatory Framework for In-Silico Drug Discovery Market in Asia-PacificTable 9: List of Advanced AI Companies Using Computational MethodsTable 10: Application of AI for COVID-19 Drug Repurposing